{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-056953","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-08-14T12:40:50+00:00","discovered_at":"2026-08-14T12:45:00.246567+00:00","generated_at":"2026-08-14T12:45:09.016494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen Q1 FY27 net loss $13.0M; cash $31.7M; FDA meeting planned for fasedienol path","bullets":["Net loss $13.0M for Q1 ended June 30, 2026, vs $15.1M year-ago; revenue $1.2M from Fuji Pharma exclusivity expiration.","Cash, equivalents and marketable securities $31.7M; sufficient into 2027 but not beyond one year from now.","PALISADE-4 missed primary endpoint overall; post-hoc very severe SAD subpopulation showed nominally significant improvement vs placebo.","FDA meeting planned this quarter to discuss potential Phase 3 registrational path for fasedienol in social anxiety disorder.","Appointed Angel S. Angelov, M.D., MBA as CMO and Douglas J. Williamson, M.D. to Board; FDA 'Study May Proceed' for refisolone."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-056953","json":"https://secwatch.observer/filing/0001628280-26-056953.json","markdown":"https://secwatch.observer/filing/0001628280-26-056953.md","text":"https://secwatch.observer/filing/0001628280-26-056953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/0001628280-26-056953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/vtgn-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:45:09.016494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}